Pulse Biosciences, Inc. (PLSE) News
Track canonical SquawkNews coverage tagged to PLSE, Pulse Biosciences, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Veeva, Revolution Medicines, Pulse Biosciences flagged as overbought
Veeva Systems reported better-than-expected second-quarter results and raised FY27 guidance above estimates, while Revolution Medicines said the FDA approved Rasonque for metastatic pancreatic adenocarcinoma. Pulse Biosc
REGULATION | Aug 27, 2026, 12:46 PM UTC
L
PLSE Oppenheimer analyst Suraj Kalia raised the firm's price target on Pulse Biosciences to $35 from $30 and keeps an Outperform rating on t
PLSE Oppenheimer analyst Suraj Kalia raised the firm's price target on Pulse Biosciences to $35 from $30 and keeps an Outperform rating on the shares. Preliminary evidence suggests nsPFA has a better safety and efficacy
EQUITY | Jul 28, 2026, 12:11 PM UTC
M
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Friday. Shares of Apogee Enterprises In c (NASDAQ: APOG ) rose sharply after the company reported better-than-expected first-quarter financ
EARNINGS | Jun 26, 2026, 01:39 PM UTC